Mutations in EZH2 are associated with poor prognosis for patients with myeloid neoplasms  

作　　者：Qi Zhang Qi Han Jie Zi Jinlong Ma Huihui Song Yulu Tian Mary McGrath Chunhua Song Zheng Ge 

机构地区：[1]Department of Hematology,Zhongda Hospital Southeast University,Institute of Hematology Southeast University,Nanjing 210009,China [2]Department of Pediatrics,Pennsylvania State University College of Medicine,Hershey,PA 17033,USA

出　　处：《Genes & Diseases》2019年第3期276-281,共6页基因与疾病（英文）

基　　金：This work is supported in part by The National Natural Science Foundation of China,China(81770172,81270613);Key Research&Technology Projects in Jiangsu Province,China(BE2017747);Milstein Medical Asian American Partnership(MMAAP)Foundation Research Project Award,USA in Hematology(2017).

摘　　要：EZH2 is a component of the polycomb repressive complex 2(PRC2),which is a highly conserved histone methyltransferase that methylates lysine 27 of histone 3.EZH2 mutations are associated with oncogenesis and progression of cancers.However,the relationship between the clinical outcome of patients with myeloid malignancies and EZH2 mutations is controversial.Therefore,we performed a meta-analysis of 8 studies(n Z 2243 patients)that evaluates the correlation between EZH2 mutations and overall survival(OS)in patients with myeloid neoplasms.EZH2 mutations were associated with significantly worse OS(hazard ratio[HR]Z 2.37,95%confidential interval(CI),1.48e3.79).In a word,EZH2 mutations indicate a poor prognosis for patients with myeloid neoplasms.

关 键 词：EZH2 META-ANALYSIS MUTATIONS Myeloid neoplasms PROGNOSTIC 

分 类 号：R73[医药卫生—肿瘤]